...
首页> 外文期刊>Biotechnology Advances: An International Review Journal >Bringing plant-based veterinary vaccines to market: Managing regulatory and commercial hurdles
【24h】

Bringing plant-based veterinary vaccines to market: Managing regulatory and commercial hurdles

机译:将基于植物的兽用疫苗推向市场:管理法规和商业障碍

获取原文
获取原文并翻译 | 示例
           

摘要

The production of recombinant vaccines in plants may help to reduce the burden of veterinary diseases, which cause major economic losses and in some cases can affect human health. While there is abundant research in this area, a knowledge gap exists between the ability to create and evaluate plant-based products in the laboratory, and the ability to take these products on a path to commercialization. The current report, arising from a workshop sponsored by an Organisation for Economic Co-operation and Development (OECD) Co-operative Research Programme, addresses this gap by providing guidance in planning for the commercialization of plant-made vaccines for animal use. It includes relevant information on developing business plans, assessing market opportunities, manufacturing scale-up, financing, protecting and using intellectual property, and regulatory approval with a focus on Canadian regulations. Crown Copyright (C) 2015 Published by Elsevier Inc.
机译:在植物中生产重组疫苗可能有助于减轻兽医疾病的负担,这会造成重大的经济损失,在某些情况下会影响人类健康。尽管在该领域有大量研究,但在实验室中创建和评估基于植物的产品的能力与将这些产品用于商业化的能力之间存在知识鸿沟。本报告是由经济合作与发展组织(OECD)合作研究计划组织的研讨会举办的,该报告通过为规划用于动物的植物性疫苗商业化提供指导,解决了这一差距。它包括有关制定业务计划,评估市场机会,扩大制造规模,融资,保护和使用知识产权以及有关加拿大法规的监管批准的相关信息。 Crown版权所有(C)2015,由Elsevier Inc.发布。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号